Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

Table 1

Patients’ characteristics, Phases I-II.

𝑁=34
Median age	72.5 (47–84)
Median DFI (months)	82 (0–120)
	𝑁	%
Performance status (ECOG)
0–1	26	76.5
2	8	23.5
Stage at enrolment
Locally advanced	0
Metastatic	34	100
Histology
Ductal carcinoma	28	82.5
Lobular carcinoma	5	14.7
Other	1	2.9
Hormone receptor status
ER+/PgR+	25	73.5
ER+/PgR−	5	14.7
ER−/PgR−	4	11.7
HER2 status
HER2−ve	28	82.3
HER2+ve	3	8.8
HER2 unknown	3	8.8
Number of metastatic site
1	7	20.6
≥2	27	79.4
Prior adjuvant therapy
None	10	29.4
Chemotherapy	7	20.6
Endocrine therapy	7	20.6
Both	10	29.4
Prior therapy for metastatic disease
None	5	14.7
Chemotherapy	2	5.8
Endocrine therapy	8	23.5
Both	18	52.9
Chemotherapy + trastuzumab	1	2.9
Number of previous chemotherapy treatments
0	13	38.2
1	13	38.2
≥2	8	23.5
Prior treatments
Anthracyclines	23	67.6
Taxanes	22	64.7